Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial

Brian I. Rini,Michael B. Atkins,Elizabeth R. Plimack,Denis Soulières,Raymond S. McDermott,Jens Bedke,Sophie Tartas,Boris Alekseev,Bohuslav Melichar,Yaroslav Shparyk,Chihiro Kondoh,Przemyslaw Langiewicz,Lori A. Wood,Hans Hammers, Cynthia G. Silber,Barbara Haber,Erin Jensen,Mei Chen,Thomas Powles

European Urology Oncology（2022）

引用 14|浏览18

暂无评分

摘要

Treatment with pembrolizumab-axitinib showed a higher incidence of grade 3 or 4 liver enzyme elevations than previously observed for monotherapy with each agent in first-line advanced renal cell carcinoma. Liver enzyme elevations could be managed successfully with prompt study treatment interruption/discontinuation, with/without corticosteroids.

查看译文

关键词

Advanced renal cell carcinoma,Aminotransferase elevations,Axitinib,Pembrolizumab,PD-1 checkpoint inhibitor,Vascular endothelial growth factor receptor inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要